These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26501120)

  • 1. Reporting of Cardiovascular Medical Device Adverse Events to Pharmaceuticals and Medical Devices Agency, Japan.
    Handa N; Ishii K; Matsui Y; Ando Y
    EBioMedicine; 2015 Sep; 2(9):1211-6. PubMed ID: 26501120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumer opinions on adverse events associated with medical devices.
    Aslani P; Hamrosi K; Tong V; Chen TF; Cook J; Fois R; McGarry T; Moore C; Peters R; Spagnardi S; Whitelock K
    Res Social Adm Pharm; 2019 May; 15(5):568-574. PubMed ID: 30100197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan.
    Ishiguro C; Takeuchi Y; Uyama Y; Tawaragi T
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):854-9. PubMed ID: 27222073
    [No Abstract]   [Full Text] [Related]  

  • 7. Implementation of adverse event reporting for medical devices, India.
    Shukla S; Gupta M; Pandit S; Thomson M; Shivhare A; Kalaiselvan V; Singh GN
    Bull World Health Organ; 2020 Mar; 98(3):206-211. PubMed ID: 32132755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of the last 15 years: from PMDEC to PMDA --looking back at the first stage of the PMDEC].
    Morimoto K; Fujiwara Y; Kawahara A
    Yakushigaku Zasshi; 2011; 46(1):38-50. PubMed ID: 22164689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of medical device--associated adverse events from emergency departments.
    Hefflin BJ; Gross TP; Schroeder TJ
    Am J Prev Med; 2004 Oct; 27(3):246-53. PubMed ID: 15450638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valacyclovir-Induced Acute Kidney Injury in Japanese Patients Based on the PMDA Adverse Drug Reactions Reporting Database.
    Kitano A; Motohashi H; Takayama A; Inui KI; Yano Y
    Ther Innov Regul Sci; 2015 Jan; 49(1):81-85. PubMed ID: 30222448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current disparities in the prices of medical materials between Japan and the United States: further investigation of cardiovascular medical devices.
    Yasunaga H; Ide H; Imamura T
    J Cardiol; 2007 Feb; 49(2):77-81. PubMed ID: 17354581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving patient care by reporting problems with medical devices.
    White GG; Weick-Brady MD; Goldman SA; Gross TP; Kennedy DL; Lucas BS; Merritt K; Naschinski C
    CRNA; 1998 Nov; 9(4):139-56. PubMed ID: 9866489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS.
    Saito S; Yamazaki K; Nishinaka T; Ichihara Y; Ono M; Kyo S; Nishimura T; Nakatani T; Toda K; Sawa Y; Tominaga R; Tanoue T; Saiki Y; Matsui Y; Takemura T; Niinami H; Matsumiya G;
    J Heart Lung Transplant; 2014 Jun; 33(6):599-608. PubMed ID: 24746637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient access to medical devices-what about Japan, the second largest medical device market?
    Ikeno F; Ikeda K; Uchida T
    Cardiovasc Interv Ther; 2014 Jan; 29(1):1-3. PubMed ID: 23975639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
    Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of safety reporting requirements during medical device clinical trials in Japan.
    Azuma K; Iseki H
    J Artif Organs; 2013 Jun; 16(2):234-41. PubMed ID: 23412831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical devices; medical device reporting; baseline reports. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jun; 73(115):33692-5. PubMed ID: 18677824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Education and training in regulatory science for medical device development.
    Sakuma I
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():3155-8. PubMed ID: 24110397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the Efficacy of Fulfillment of Medical Device Adverse Event Monitoring Entities and Safeguard Mechanism].
    Ren W; Mao Y; Luo W; Ding J; Wang W; Zhu Q
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Jan; 42(1):58-61. PubMed ID: 29862750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.